On March 20  2024, Antoine Klauser, from Siemens Healthineers, shared his talk on “MR spectroscopy and spectroscopic imaging at 7T, challenges and opportunities” at the Campus Biotech in Geneva.


Magnetic Resonance Spectroscopic (MRS) is a well-established molecular MR imaging modality, facilitating non-invasive exploration of in-vivo metabolism. In particular, MRS can simultaneously measure up to 20 brain metabolites. Among various MRI modalities, MRS stands to gain the most from ultra-high field strengths (7T and above) thanks to the increased spectral dispersion and signal-to-noise ratio (SNR). However, its implementation at 7T poses several challenges that hinder its direct application. Leveraging these challenges, novel MR spectroscopic imaging (MRSI) techniques have emerged, such as Free Induction Decay – MRSI (FID-MRSI), enabling high-resolution metabolite mapping across the whole brain with fast acquisition schemes. In this presentation, I will discuss both the advantages and challenges of using MRS at 7T, and share the latest advancements in FID-MRSI for high-resolution metabolite mapping of the entire brain.

Antoine Klauser

Antoine Klauser

Siemens Healthineers

Antoine, a physicist by training, transitioned from condensed matter theoretical physics (PhD, 2012) to clinical neuroscience research, focusing on multiple sclerosis from 2012 to 2015. Recognizing the need for new MR imaging tools, he shifted his focus to the developing of imaging methods, particularly MRSI, at CIBM from 2015 onwards. His expertise led to a collaboration with the Martinos Center at MGH in 2019, where he developed advanced techniques for high-resolution MRSI acquisition at 7 Tesla. In 2022, he joined Siemens Healthineers as an On-Site Research Scientist at Campus Biotech, Geneva, driving innovation in MRI technology for research and clinical applications.


Comments are closed.